Fakhouri, Fadi <br/><br/>
Terminal Complement Inhibitor Eculizumab in Adult Patients With Atypical Hemolytic Uremic Syndrome: A Single-Arm, Open-Label Trial.  [electronic resource] 

 -  American journal of kidney diseases : the official journal of the National Kidney Foundation  Jul 2016 
 - 84-93 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study 
<br/><br/><label>ISSN: </label>1523-6838 
<br/><br/><label>Standard No.: </label>10.1053/j.ajkd.2015.12.034  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antibodies, Monoclonal, Humanized--therapeutic use<br/>Atypical Hemolytic Uremic Syndrome--drug therapy<br/>Female<br/>Humans<br/>Male<br/>Middle Aged<br/>Prospective Studies<br/>Remission Induction<br/>Young Adult